Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Imaging for Response Assessment of Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer

NCT01690325 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT01690325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01690325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Imaging for Response Assessment of Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2012
Completion date
November 30, 2016
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer